Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer

  • Ghalhar, Masoud Gandomkar (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Akbarzadeh, Abolfazl (Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Rahmati, Mohammad (Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Mellatyar, Hassan (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Dariushnejad, Hassan (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Zarghami, Nosratallah (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Barkhordari, Amin (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
  • Published : 2014.09.15


Background: HSP90 may be overexpressed in cancer cells which are greatly dependent on Hsp90 function. Geldanamycin derivative 17 allylamino-17-demethoxygeldanamycin (17-AAG) inhibits the function and expression of HSP90. 17-AAG has poor water-solubility which is a potential problem for clinical practice. In this study for improving the stability and solubility of molecules in drug delivery systems we used a ${\beta}$-cyclodextrin-17AAG complex. Materials and Methods: To assess cytotoxic effects of ${\beta}$-cyclodextrin-17AAG complexes and free 17AAG, colorimetric cell viability (MTT) assays were performed. Cells were treated with equal concentrations of ${\beta}$-cyclodextrin- 17AAG complex and free 17AAG and Hsp90 gene expression levels in the two groups was compared by real-time PCR. Results: MTT assay confirmed that ${\beta}$-cyclodextrin- 17AAG complex enhanced 17AAG cytotoxicity and drug delivery in T47D breast cancer cells. The level of Hsp90 gene expression in cells treated with ${\beta}$-cyclodextrin- 17AAG complex was lower than that of cells treated with free 17AAG (P=0.001). Conclusions: The results demonstrated that ${\beta}$-cyclodextrin- 17AAG complexes are more effective than free 17AAG in down-regulating HSP90 expression due to enhanced ${\beta}$-cyclodextrin-17AAG uptake by cells. Therefore, ${\beta}$-cyclodextrin could be superior carrier for this kind of hydrophobic agent.


  1. Akbarzadeh A, Nejati-Koshki K, Mahmoudi Soghrati M, et al (2013). In vitro studies of NIPAAM-MAA-VP copolymercoated magnetic nanoparticles for controlled anticancer drug release. JEAS, 3, 108-15.
  2. Ahmadi A, Shirazi H, Pourbagher N, Akbarzadeh A, Omidfar K (2014). An electrochemical immunosensor for digoxin using core-shell gold coated magnetic nanoparticles as labels. Mol Biol Rep, 41, 1659-68.
  3. Akbarzadeh A, Rezaei A, Nejati-Koshki K, et al (2014). Synthesis and physicochemical characterization of biodegradable star-shaped poly lactide-co-glycolide- $\beta$-cyclodextrin copolymer nanoparticles containing albumin, J Adv Nanoparticles, 3, 1-9.
  4. Akbarzadeh A, Rezaei-Sadabady R, Zarghami N, et al (2013). Studies of the relationship between structure and antioxidant activity in interesting systems, including tyrosol, hydroxytyrosol derivatives indicated by quantum chemical calculations. Soft, 2, 13-8.
  5. Akbarzadeh A, Samiei M, Davaran S (2012). Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett, 7, 14-26.
  6. Akbarzadeh A, Samiei M, Joo SW, (2012). Synthesis, characterization and In vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnol, 10, 46-52.
  7. Akbarzadeh A, Zarghami N, Mikaeili H, et al (2012). Synthesis, characterization and In vitro evaluation of novel polymercoated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol Sci Appl, 5, 13-25.
  8. Ebrahimnezhad Z, Zarghami N, Keyhani M, et al (2013). Inhibition of hTERT gene expression by silibinin-loaded PLGA-PEG-$Fe_3O_4$ in T47D breast cancer cell line. Bioimpacts, 3, 67-74.
  9. Bagatell R, Whitesell L (2004). Altered Hsp90 function in cancer: a unique therapeutic opportunity. Molecular Cancer Therapeutics, 3, 1021-30.
  10. Challa R, Ahuja A, Ali J, Khar R (2005). Cyclodextrins in drug delivery: an updated review. Aaps Pharmscitech, 6, 329-57.
  11. Davaran S (2014). Physicochemical characteristics of Fe. Asian Pac J Cancer Prev, 15, 49-54.
  12. Fukuyo Y, Hunt CR, Horikoshi N (2010). Geldanamycin and its anti-cancer activities. Cancer Lett, 290, 24-35.
  13. Ge QD, Lv N, Kong YN, et al (2012). Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. Asian Pac J Cancer Prev, 13, 5081-6.
  14. Akbarzadeh A, Hosseininasab S, Davaran S, et al (2014). Synthesis, characterization, and In vitro studies of PLGAPEG nanoparticles for oral Insulin delivery. Chem Biol Drug Des, 3, 1-9.
  15. Akbarzadeh A, Mikaeili H, Zarghami N, et al (2012). Preparation and in-vitro evaluation of doxorubicin-loaded $Fe_3O_4$ magnetic nanoparticles modified with biocompatible copolymer. Int J Nanomedicine, 7, 1-16.
  16. Ghasemali S, Nejati-Koshki K, Tafsiri E, et al (2013). Inhibitory effects of -cyclodextrin-helenalin complexes on H-TERT gene expression in the T47D breast cancer cell line-results of real time quantitative PCR. Asian Pac J Cancer Prev, 14, 6949-53.
  17. Guo W, Siegel D, Ross D (2008). Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal catalyzed oxidation. J Pharm Sci, 97, 5147-57.
  18. Karkoulis PK, Stravopodis DJ, Margaritis LH, Voutsinas GE (2010). 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer, 10, 481.
  19. Kouhi M, Vahedi A, Akbarzadeh A, et al (2014). Investigation of quadratic electro-optic effects and electro-absorption process in GaN/AlGaN spherical quantum dot. Nanoscale Res Lett, 9, 1-6.
  20. Mirakabad FT, Akbarzadeh A, Zarghami N, et al (2013). PLGAbased nanoparticles as cancer drug delivery systems. In: 1st Tabriz International Life Science Conference and 12th Iran Biophysical Chemistry Conference, Tabriz university of medical sciences.
  21. Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effect of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-8.
  22. Najafi B, Anvari S, Roshan ZA, et al (2013). Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2010 in Iran. Asian Pac J Cancer Prev, 14, 5811-6.
  23. Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, et al (2013). Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pac J Cancer Prev, 14, 6595-9.
  24. Pick E, Kluger Y, Giltnane JM, et al (2007). High HSP90 expression is associated with decreased survival in breast cancer. Cancer research, 67, 2932-7.
  25. Pourhassan-Moghaddam M, Rahmati-Yamchi M, Akbarzadeh A, et al (2013). Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale research letters, 8, 1-11.
  26. Richardson PG, Mitsiades CS, Laubach JP, et al (2011). Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J haematol, 152, 367-79.
  27. Sakthivel K, Kannan N, Angeline A, Guruvayoorappan C (2012). Anticancer activity of acacia nilotica (L.) Wild. Ex. Delile subsp. indica against Dalton's ascitic lymphoma induced solid and ascitic tumor model. Asian Pac J Cancer Prev, 13, 3989-95.
  28. Schulz R, Marchenko ND, Holembowski L, et al (2012). Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med, 209, 275-89.
  29. Tsuda H (2010). Risk assessment studies of nanomaterials in Japan and other countries. Asian Pac J Cancer Prev 11
  30. Usmani SZ and Chiosis G (2011). HSP90 inhibitors as therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk, 11, 77-81.
  31. Valizadeh A, Mikaeili H, Samiei M, et al (2012). Quantum dots: synthesis, bioapplications, and toxicity. Nanoscale Res Lett, 7, 1-14.
  32. Wang H-H, Song YX, Bai M, et al (2014). Ultrasound targeted microbubble destruction for novel dual targeting of hsp72 and hsc70 in prostate cancer. Asian Pac J Cancer Prev: APJCP, 15, 1285.
  33. Yadav D, Anwar MF, Garg V, et al (2014). Development of polymeric nanopaclitaxel and comparison with free paclitaxel for effects on cell proliferation of MCF-7 and B16F0 carcinoma cells. Asian Pac J Cancer Prev, 15, 2335-40.
  34. Yallapu MM, Jaggi M, Chauhan SC, et al (2012). Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discovery Today. 17, 71-80.
  35. Yin H-T, Zhang D, Wu X, et al (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12.
  36. Zajac M, Gomez G, Benitez J, et al (2010). Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer. BMC Medical Genomics, 3, 44.

Cited by

  1. Comparison, synthesis and evaluation of anticancer drug-loaded polymeric nanoparticles on breast cancer cell lines pp.2169-141X, 2015,
  2. Magnetic nanoparticles: Applications in gene delivery and gene therapy pp.2169-141X, 2015,
  3. Current methods for synthesis of magnetic nanoparticles vol.44, pp.2, 2016,
  4. Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells pp.2169-141X, 2017,
  5. Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed, in vitro, on Leishmania (L) amazonensis Amastigotes-Hosted in Mouse CBA Macrophages vol.8, pp.2235-2988, 2018,
  6. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment pp.17470277, 2019,